Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Clin Infect Dis
    February 2026
  1. MITHA E, Ferguson M, Wilhase AC, De Looze F, et al
    Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged >/=60 Years.
    Clin Infect Dis. 2026 Feb 27:ciag058. doi: 10.1093.
    >> Share

  2. NELLORE A, Bajema K, Belden K, Blumberg D, et al
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients.
    Clin Infect Dis. 2026 Feb 25:ciag115. doi: 10.1093.
    >> Share

  3. HOLLAND C, Le H, Levy A, Minney-Smith C, et al
    Maternal influenza vaccine reduces the risk of RSV and related respiratory hospitalisations in early infancy: an epidemiological study.
    Clin Infect Dis. 2026 Feb 25:ciag131. doi: 10.1093.
    >> Share

  4. MAYER EF, Falsey AR, Wolfe CR, Herc E, et al
    RSV Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345.
    Clin Infect Dis. 2026 Feb 18:ciag108. doi: 10.1093.
    >> Share

  5. SUMSUZZMAN DM, Shi C, Moghadas SM
    Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalisation and Emergency Department Visits Associated with Respiratory Syncytial Virus in Older Adults: A Meta-Analysis.
    Clin Infect Dis. 2026 Feb 18:ciag107. doi: 10.1093.
    >> Share

  6. AABY P, Biering-Sorensen S, Lund N, Jensen KJ, et al
    Misleading comments about the impact of early BCG vaccination on neonatal and infant mortality.
    Clin Infect Dis. 2026 Feb 4:ciag065. doi: 10.1093.
    >> Share

  7. MAYER EF, Falsey AR, Clark R, Ferguson M, et al
    Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years.
    Clin Infect Dis. 2026;81:e708-e716.
    >> Share

  8. DAGAN R, van der Beek BA, Grupel T, Greenberg D, et al
    Decline in Community-Acquired Alveolar Pneumonia Positive for Respiratory Syncytial Virus in Hospitalized Children Following Implementation of Pneumococcal Conjugate Vaccine (PCV) in Israel.
    Clin Infect Dis. 2026;81:e690-e699.
    >> Share

  9. MA KC, Surie D, Dean N, Paden CR, et al
    Integrating genomic data into test-negative designs for estimating lineage-specific COVID-19 vaccine effectiveness.
    Clin Infect Dis. 2026 Feb 2:ciag059. doi: 10.1093.
    >> Share

    January 2026
  10. ASTURIAS EJ, Schechter R, Talbot HK, Boom J, et al
    The Erosion of a Pillar of Public Health: ACIP's Role and the Future of U.S. Vaccine Policy Post-June 2025.
    Clin Infect Dis. 2026 Jan 29:ciag042. doi: 10.1093.
    >> Share

  11. WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al
    Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18?55 Years Old.
    Clin Infect Dis. 2026 Jan 21:ciag026. doi: 10.1093.
    >> Share

  12. PURPURA L, Heisler T, Palmer S, Shah J, et al
    Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.
    Clin Infect Dis. 2026 Jan 9:ciaf624. doi: 10.1093.
    >> Share

    December 2025
  13. SHAHAR E
    Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection.
    Clin Infect Dis. 2025 Dec 31:ciaf735. doi: 10.1093.
    >> Share

  14. LAI SW, Chiu SC
    Herpes zoster, vaccine, and stroke risk.
    Clin Infect Dis. 2025 Dec 26:ciaf725. doi: 10.1093.
    >> Share

  15. HELLNER K, Simon P, De Sutter P, Vahula KL, et al
    A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-Risk Human Papillomavirus Vaccine in Women w
    Clin Infect Dis. 2025 Dec 17:ciaf658. doi: 10.1093.
    >> Share

  16. MACHIDA M, Fukushima W
    Vaccine Policy Pendulum: a Lesson from Japan.
    Clin Infect Dis. 2025 Dec 11:ciaf689. doi: 10.1093.
    >> Share

  17. BRASSINGTON E, Fairhead C, Hill A
    Is it time to reassess the target age of HPV vaccination globally?
    Clin Infect Dis. 2025 Dec 9:ciaf679. doi: 10.1093.
    >> Share

  18. LODHA L, Gupta S, Ashwini MA, Chandel S, et al
    Rabies Despite Post-Exposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery?
    Clin Infect Dis. 2025 Dec 6:ciaf662. doi: 10.1093.
    >> Share

    November 2025
  19. SCOTT PT, Pathirana J, Kato A, Tytus R, et al
    A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naive Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE
    Clin Infect Dis. 2025 Nov 10:ciaf604. doi: 10.1093.
    >> Share

    October 2025
  20. FONG Y, Huang Y, Huang Y, Woo W, et al
    Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine.
    Clin Infect Dis. 2025 Oct 25:ciaf558. doi: 10.1093.
    >> Share

  21. TARTOF SY, Aliabadi N, Goodwin G, Slezak J, et al
    Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season.
    Clin Infect Dis. 2025 Oct 21:ciaf496. doi: 10.1093.
    >> Share

  22. GAGLANI M, Raiyani C, Murthy K, Smith M, et al
    Absolute and Relative Effectiveness of Cell- and Egg-based Quadrivalent Inactivated Influenza Vaccine Products from 2014-2015 to 2018-2019 seasons, U.S. Flu VE Network.
    Clin Infect Dis. 2025 Oct 16:ciaf579. doi: 10.1093.
    >> Share

  23. BELSHE RB, Bernstein DI, Edwards KM, Frey SE, et al
    Vaccine and Treatment Evaluation Units: A Historical Perspective.
    Clin Infect Dis. 2025;81.
    >> Share

  24. JANO K, Babu TM, Kottkamp AC, Rebolledo PA, et al
    Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.
    Clin Infect Dis. 2025;81.
    >> Share

  25. DOBRZYNSKI DM, Graciaa DS, Babu TM, Coler RN, et al
    From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.
    Clin Infect Dis. 2025;81.
    >> Share

  26. WHITAKER JA, Collins MH, Rebolledo PA, Dobrzynski D, et al
    Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.
    Clin Infect Dis. 2025;81.
    >> Share

  27. ATMAR RL, Abate G, Deming ME, George SL, et al
    Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.
    Clin Infect Dis. 2025;81.
    >> Share

  28. ERBELDING EJ, Marrazzo JM
    Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?
    Clin Infect Dis. 2025;81.
    >> Share

  29. BELONGIA EA, Nguyen HQ, McClure DL, Lewis N, et al
    Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.
    Clin Infect Dis. 2025 Oct 9:ciaf563. doi: 10.1093.
    >> Share

  30. STAFFORD E, Dimitrov D, Trinidad SB, Matrajt L, et al
    Closing the Gap in Race-based Inequities for Seasonal Influenza Hospitalizations: A Modeling Study.
    Clin Infect Dis. 2025;81:478-487.
    >> Share

    September 2025
  31. CARAZO S, Phimmasone J, Skowronski DM, Giguere K, et al
    Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-Omicron and Omicron periods.
    Clin Infect Dis. 2025 Sep 29:ciaf549. doi: 10.1093.
    >> Share

  32. GOSWAMI J, Cardona JF, Caso J, Hsu DC, et al
    Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years.
    Clin Infect Dis. 2025 Sep 23:ciaf515. doi: 10.1093.
    >> Share

  33. COLOMBO RE, Richard SA, Schmidt K, Schofield C, et al
    Randomized pragmatic trial of the comparative effectiveness of chicken egg-based inactivated, mammalian cell-culture-based inactivated, and recombinant protein quadrivalent seasonal influenza vaccines in United States Military Health System beneficiar
    Clin Infect Dis. 2025 Sep 18:ciaf503. doi: 10.1093.
    >> Share

  34. SHETTY AN, Hennessy D, Kattan GS, Ojaimi S, et al
    Transient increased risk of shingles post Shingrix vaccination: Self-controlled case series analysis.
    Clin Infect Dis. 2025 Sep 9:ciaf473. doi: 10.1093.
    >> Share

  35. GODIN A, Brickley EB, Connor RI, Wieland-Alter WF, et al
    Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newborns.
    Clin Infect Dis. 2025 Sep 5:ciaf484. doi: 10.1093.
    >> Share

    August 2025
  36. REZAHOSSEINI O, Staehr Jensen JU, Rahimi HK, Jensen NE, et al
    Immunogenicity and Safety of the COVID-19 mRNA Vaccine Coadministered with Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.
    Clin Infect Dis. 2025 Aug 18:ciaf455. doi: 10.1093.
    >> Share

  37. RAYENS E, Sy LS, Qian L, Wu J, et al
    Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged >/=50 years.
    Clin Infect Dis. 2025 Aug 9:ciaf440. doi: 10.1093.
    >> Share

  38. RON R, Diaz-Garcia C, Sendagorta E, Cabello-Ubeda A, et al
    A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.
    Clin Infect Dis. 2025 Aug 6:ciaf435. doi: 10.1093.
    >> Share

  39. SCHNYDER JL, Haggenburg S, Garcia Garrido HM, Reiners A, et al
    Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV - 3-year follow-up of a pr
    Clin Infect Dis. 2025 Aug 6:ciaf438. doi: 10.1093.
    >> Share

    July 2025
  40. PARRA G, Lessa FC, Campelo E, Amorim Ramos TC, et al
    Incidence of and Risk Factors for SARS-CoV-2 Infection Among Vaccinated Healthcare Workers During Emergence of SARS-CoV-2 Gamma Variant in the Amazon Region, Brazil, 2021.
    Clin Infect Dis. 2025 Jul 30:ciaf339. doi: 10.1093.
    >> Share

  41. HUNDIE GB, Ashengo TA, Stender SC, Abraha M, et al
    Assessing Coronavirus Disease 2019 Vaccination Uptake and Incident Infections Among Ethiopian Healthcare Workers, Addis Ababa-2022: Implications for Public Health Preparedness.
    Clin Infect Dis. 2025 Jul 29:ciaf341. doi: 10.1093.
    >> Share

  42. PONCE D, Westercamp M, Soto G, Lessa FC, et al
    COVID-19 Exposure, Protective Measures, Symptom Assessment, and Risk Perception Among Healthcare Workers in Peru: A Longitudinal Cohort Study (2020-2021).
    Clin Infect Dis. 2025 Jul 29:ciaf343. doi: 10.1093.
    >> Share

  43. CHISSUMBA RM, Kwatra G, Ramgi P, Enosse M, et al
    Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clin Infect Dis. 2025;80.
    >> Share

  44. KANG SSY, Tadesse BT, Jeon HJ, Fallah MP, et al
    Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    >> Share

  45. KIM CL, Thwe TT, Espinoza LMC, Sugimoto JD, et al
    Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    >> Share

  46. RAMGI P, Siribie M, Rakotozandrindrainy N, Bule O, et al
    Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.
    Clin Infect Dis. 2025;80.
    >> Share

  47. CAPITINE IU, Aziz AB, Manhica A, Tivane I, et al
    Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.
    Clin Infect Dis. 2025;80.
    >> Share

  48. DE SCHACHT C, Capitine IU, Lucas C, Muteerwa A, et al
    Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.
    Clin Infect Dis. 2025;80.
    >> Share

  49. SIZA C, Plucinski M, Lessa FC, Campelo E, et al
    Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
    Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
    >> Share

  50. MANNING JE, Beckers F, de Bruijn I, Sridhar S, et al
    First Among Equals: The Case for High-quality Clinical Data in Influenza Vaccines.
    Clin Infect Dis. 2025 Jul 15:ciaf290. doi: 10.1093.
    >> Share

  51. WANG B, Giles L, Andraweera P, McMillan M, et al
    Long-term protection against invasive meningococcal B disease and gonococcal infection five years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study.
    Clin Infect Dis. 2025 Jul 10:ciaf372. doi: 10.1093.
    >> Share

    June 2025
  52. TSENG HF, Sy LS, Ackerson BK, Rayens E, et al
    Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults >/=50 Years in the United States.
    Clin Infect Dis. 2025 Jun 23:ciaf329. doi: 10.1093.
    >> Share

  53. XHAFERI A, Bino S, Daja R, Vasili A, et al
    Sociodemographic and Occupational Factors Associated With Coronavirus Disease 2019 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022-2023: A Multicenter Study.
    Clin Infect Dis. 2025 Jun 3:ciaf202. doi: 10.1093.
    >> Share

    May 2025
  54. CHUMAKOV K, Plotkin SA
    Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication.
    Clin Infect Dis. 2025 May 21:ciaf215. doi: 10.1093.
    >> Share

  55. MEHMOOD N, Alam MM, Arshad Y, Akhtar R, et al
    Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019-2021.
    Clin Infect Dis. 2025 May 21:ciaf151. doi: 10.1093.
    >> Share

  56. KU JH, Gu YM, Hoke CF, Tseng HF, et al
    Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system.
    Clin Infect Dis. 2025 May 20:ciaf251. doi: 10.1093.
    >> Share

  57. REGAN JJ, Wang Z, Phares CR
    The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the US Immigration Medical Examination: Are Vaccines Causing False-Negative Results?
    Clin Infect Dis. 2025 May 15:ciaf129. doi: 10.1093.
    >> Share

  58. KONOPNICKI D, Gilles C, Manigart Y, Barlow P, et al
    Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
    Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093.
    >> Share

  59. AMARIN JZ, Toepfer AP, Spieker AJ, Hayek H, et al
    Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016-2020.
    Clin Infect Dis. 2025 May 9:ciaf194. doi: 10.1093.
    >> Share

    April 2025
  60. TORCEL-PAGNON L, Coudeville L, Harris RC, Chaves SS, et al
    The Impact of Influenza on US Working-Age Adults: Exploring the Benefits of the Recombinant Influenza Vaccine.
    Clin Infect Dis. 2025 Apr 17:ciaf200. doi: 10.1093.
    >> Share

  61. MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al
    Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
    Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093.
    >> Share

  62. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post-Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras.
    Clin Infect Dis. 2025 Apr 10:ciaf087. doi: 10.1093.
    >> Share

  63. FOX A, Sanchez-Ovando S, Carolan L, Hadiprodjo AJ, et al
    Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.
    Clin Infect Dis. 2025 Apr 3:ciaf060. doi: 10.1093.
    >> Share

    March 2025
  64. KELLY JD, Hoggatt KJ, Lo NC, Leonard S, et al
    Annual variant-targeted vaccination to prevent severe COVID-19 disease in cohorts with vaccine-derived and hybrid immunity.
    Clin Infect Dis. 2025 Mar 14:ciaf124. doi: 10.1093.
    >> Share

    February 2025
  65. DAVIDO B, Kharkhordine M
    Enhancing Influenza Vaccination for Adults Aged 50-64: Addressing Moderate Vaccine Efficacy.
    Clin Infect Dis. 2025 Feb 20:ciaf070. doi: 10.1093.
    >> Share

  66. WALSH EE, Eiras D, Woodside J, Jiang Q, et al
    Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons.
    Clin Infect Dis. 2025 Feb 10:ciaf061. doi: 10.1093.
    >> Share

    January 2025
  67. BANOONI P, Gonik B, Epalza C, Reyes O, et al
    Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine.
    Clin Infect Dis. 2025 Jan 29:ciaf033. doi: 10.1093.
    >> Share


  68. Correction to: Incidence of Tetanus and Diphtheria in Relation to Adult Vaccination Schedules.
    Clin Infect Dis. 2025 Jan 15:ciaf014. doi: 10.1093.
    >> Share

  69. CHUNG JR, Price AM, Zimmerman RK, Moehling Geffel K, et al
    Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season.
    Clin Infect Dis. 2025 Jan 6:ciae658. doi: 10.1093.
    >> Share

    December 2024
  70. BIRABAHARAN M, Johns ST, Kaelber DC, Martin TCS, et al
    Atrial Fibrillation after RSV Vaccination Among Older Adults.
    Clin Infect Dis. 2024 Dec 26:ciae649. doi: 10.1093.
    >> Share

  71. NOLAN T, Bhusal C, Hoberman A, Llapur CJ, et al
    Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study.
    Clin Infect Dis. 2024 Dec 26:ciae622. doi: 10.1093.
    >> Share

  72. PLOTKIN SA, Shapiro ED
    The Current and Future State of Vaccines for Lyme Disease.
    Clin Infect Dis. 2024 Dec 23:ciae639. doi: 10.1093.
    >> Share

  73. WANG X, Patel C, Giles ML, Burns P, et al
    Glucocorticoid dosing and implications for vaccination: Evolution of global definitions.
    Clin Infect Dis. 2024 Dec 18:ciae613. doi: 10.1093.
    >> Share

  74. DAGAN R, van der Beek BA
    Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine is Reduced in Infants Immunized during the Respiratory Viral Season.
    Clin Infect Dis. 2024 Dec 17:ciae619. doi: 10.1093.
    >> Share

  75. WEE LE, Lim JT, Goel M, Malek MIA, et al
    Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough SARS-CoV-2 Omicron infection: a cohort study.
    Clin Infect Dis. 2024 Dec 5:ciae598. doi: 10.1093.
    >> Share

  76. TENFORDE MW, Reeves EL, Weber ZA, Tartof SY, et al
    Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States.
    Clin Infect Dis. 2024 Dec 4:ciae597. doi: 10.1093.
    >> Share

    November 2024
  77. TOWNSEND JP, Hassler HB, Dornburg A
    Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
    Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
    >> Share

  78. CHOKEPHAIBULKIT K, Huoi C, Tantawichien T, Mootsikapun P, et al
    Non-inferiority study of purified Vero rabies vaccine - serum free in three-dose and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies vaccines.
    Clin Infect Dis. 2024 Nov 26:ciae581. doi: 10.1093.
    >> Share


  79. Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.
    Clin Infect Dis. 2024 Nov 15:ciae504. doi: 10.1093.
    >> Share


  80. Correction to: Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination.
    Clin Infect Dis. 2024 Nov 15:ciae506. doi: 10.1093.
    >> Share

  81. DAVIS M, Towner W, DeHaan E, Jiang Q, et al
    Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.
    Clin Infect Dis. 2024 Nov 11:ciae550. doi: 10.1093.
    >> Share

  82. ROGERS JH, Westley B, Mego T, Newell KG, et al
    Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.
    Clin Infect Dis. 2024 Nov 5:ciae536. doi: 10.1093.
    >> Share

  83. VAN DER STAAK M, Ten Hulscher HI, Nicolaie AM, Smits GP, et al
    Long-term dynamics of measles virus-specific neutralizing antibodies in children vaccinated before 12 months of age.
    Clin Infect Dis. 2024 Nov 4:ciae537. doi: 10.1093.
    >> Share

    October 2024
  84. WHITE EB, Grant L, Mak J, Olsho L, et al
    Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
    Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093.
    >> Share

  85. TAN SK, Cebrik D, Plotnik D, Agostini ML, et al
    A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).
    Clin Infect Dis. 2024;79:1054-1061.
    >> Share

  86. SELF WH, Johnson KD, Resser JJ, Whitney CG, et al
    Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022.
    Clin Infect Dis. 2024;79:838-847.
    >> Share

  87. BEGLEY KM, Leis AM, Petrie JG, Truscon R, et al
    Epidemiology of Respiratory Syncytial Virus in Adults and Children With Medically Attended Acute Respiratory Illness Over Three Seasons.
    Clin Infect Dis. 2024;79:1039-1045.
    >> Share

  88. MONTANO M, Shapiro AE, Whitney BM, Bamford L, et al
    Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort.
    Clin Infect Dis. 2024 Oct 8:ciae464. doi: 10.1093.
    >> Share

    September 2024
  89. FONG Y, Dang L, Zhang B, Fintzi J, et al
    Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
    >> Share

  90. LEUNG J, Munir NA, Mathis AD, Filardo TD, et al
    The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Post-Elimination Era, 2001-2022.
    Clin Infect Dis. 2024 Sep 13:ciae470. doi: 10.1093.
    >> Share

  91. PLOTKIN SA, Robinson JM, Fitchett JRA, Gershburg E, et al
    Vaccine Development Should Be Polytheistic, Not Monotheistic.
    Clin Infect Dis. 2024 Sep 6:ciae460. doi: 10.1093.
    >> Share

    August 2024

  92. Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged >/=18 Years.
    Clin Infect Dis. 2024 Aug 29:ciae389. doi: 10.1093.
    >> Share


  93. Correction to: Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Clin Infect Dis. 2024 Aug 28:ciae390. doi: 10.1093.
    >> Share

  94. DONSKEY CJ, Dubberke ER, Klein NP, Liles EG, et al
    CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
    Clin Infect Dis. 2024 Aug 24:ciae410. doi: 10.1093.
    >> Share

  95. KUIJPER EJ, Gerding DN
    The end of toxoid vaccine development for preventing Clostridioides difficile infections?
    Clin Infect Dis. 2024 Aug 24:ciae412. doi: 10.1093.
    >> Share

  96. KU JH, Rayens E, Sy LS, Qian L, et al
    Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults >/=65 Years of Age.
    Clin Infect Dis. 2024 Aug 21:ciae375. doi: 10.1093.
    >> Share

  97. BERTHAUD V, Creech CB, Rostad CA, Carr Q, et al
    Safety and Immunogenicity of an mRNA-1273 Booster in Children.
    Clin Infect Dis. 2024 Aug 19:ciae420. doi: 10.1093.
    >> Share

  98. JAYASINGHE S, Williams PCM, Macartney KK, Crawford NW, et al
    Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study.
    Clin Infect Dis. 2024 Aug 14:ciae377. doi: 10.1093.
    >> Share

  99. MA KC, Surie D, Lauring AS, Martin ET, et al
    Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093.
    >> Share

  100. FERGUSON M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, et al
    Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age.
    Clin Infect Dis. 2024 Aug 5:ciae364. doi: 10.1093.
    >> Share

  101. CLARK R, Davies S, Labrador J, Loubet P, et al
    Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.
    Clin Infect Dis. 2024 Aug 5:ciae365. doi: 10.1093.
    >> Share

  102. BRANCHE AR
    We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in Adults: What Else Do We Need to Know About How to Use Them?
    Clin Infect Dis. 2024 Aug 5:ciae362. doi: 10.1093.
    >> Share

    July 2024
  103. SCOTT P, Haranaka M, Choi JH, Stacey H, et al
    A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (Stride-6).
    Clin Infect Dis. 2024 Jul 31:ciae383. doi: 10.1093.
    >> Share

  104. COWLING BJ, Wong SS, Santos JJS, Touyon L, et al
    Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.
    Clin Infect Dis. 2024 Jul 23:ciae380. doi: 10.1093.
    >> Share

  105. EDOSA M, Jeon Y, Gedefaw A, Hailu D, et al
    Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.
    Clin Infect Dis. 2024;79.
    >> Share

  106. HUSSEN M, Worku Demlie Y, Edosa M, Kebede M, et al
    Ethiopia National Cholera Elimination Plan 2022-2028: Experiences, Challenges, and the Way Forward.
    Clin Infect Dis. 2024;79.
    >> Share

  107. PARK SE, Gedefaw A, Hailu D, Jeon Y, et al
    Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
    Clin Infect Dis. 2024;79.
    >> Share

  108. BORJA-TABORA C, Fernando L, Lopez Medina E, Reynales H, et al
    Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group.
    Clin Infect Dis. 2024 Jul 12:ciae369. doi: 10.1093.
    >> Share

  109. JOHNSTON TS, Hage C, Abedon AT, Panda S, et al
    Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Jul 2:ciae279. doi: 10.1093.
    >> Share

    June 2024
  110. CHONG C, Wee LE, Jin X, Zhang M, et al
    Risks of SARS-CoV-2 JN.1 infection and COVID-19 associated emergency-department (ED) visits/hospitalizations following updated boosters and prior infection: a population-based cohort study.
    Clin Infect Dis. 2024 Jun 26:ciae339. doi: 10.1093.
    >> Share

  111. RUSS RK, Vandehei HM, Golovkina MI, Mogallapalli H, et al
    Hepatitis B-CpG vaccine series for healthcare workers who are hepatitis B vaccine nonresponders.
    Clin Infect Dis. 2024 Jun 17:ciae320. doi: 10.1093.
    >> Share

  112. BOECKH M, Pergam SA, Limaye AP, Englund J, et al
    How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic.
    Clin Infect Dis. 2024 Jun 3:ciae308. doi: 10.1093.
    >> Share

    May 2024
  113. WOLFE DN, Arangies E, David GL, Armstrong B, et al
    Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
    Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
    >> Share

  114. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
    SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
    >> Share

  115. JORGENSEN SCJ, Brown K, Clarke AE, Schwartz KL, et al
    The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study.
    Clin Infect Dis. 2024 May 3:ciae182. doi: 10.1093.
    >> Share

    April 2024

  116. Correction to: Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Apr 30:ciae164. doi: 10.1093.
    >> Share

  117. MWESIGWA B, Sawe F, Oyieko J, Mwakisisile J, et al
    Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
    Clin Infect Dis. 2024 Apr 24:ciae215. doi: 10.1093.
    >> Share

  118. HASAN T, Lynch M, King C, Wehbe C, et al
    Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review.
    Clin Infect Dis. 2024 Apr 17:ciae209. doi: 10.1093.
    >> Share


  119. Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients.
    Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093.
    >> Share

  120. SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al
    COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
    Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093.
    >> Share

  121. FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al
    Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL-March 2023-June 2023.
    Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093.
    >> Share

  122. SU WJ, Chen HL, Chen SF, Liu YL, et al
    Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-vaccination Serologic Testing.
    Clin Infect Dis. 2024 Apr 2:ciae176. doi: 10.1093.
    >> Share

    March 2024
  123. ROSTAD CA, Atmar RL, Walter EB, Frey S, et al
    A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US
    Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093.
    >> Share

  124. PINEDA-PENA AC, Jiang Q, Petit C, Korejwo-Peyramond J, et al
    Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free, Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized Controlled Phase III Trial.
    Clin Infect Dis. 2024 Mar 13:ciae137. doi: 10.1093.
    >> Share

  125. SHRESTHA NK, Burke PC, Nowacki AS, Gordon SM, et al
    Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine.
    Clin Infect Dis. 2024 Mar 11:ciae132. doi: 10.1093.
    >> Share

  126. ROMINE JK, Li H, Coughlin MM, Jones JM, et al
    Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study.
    Clin Infect Dis. 2024 Mar 11:ciae130. doi: 10.1093.
    >> Share

    February 2024
  127. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
    Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
    Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
    >> Share

    December 2023
  128. THOMAS LD, Batarseh E, Hamdan L, Haddadin Z, et al
    Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
    Clin Infect Dis. 2023;77:1723-1732.
    >> Share

  129. RYBAK A, Assad Z, Levy C, Bonarcorsi S, et al
    Age-specific resurgence in invasive pneumococcal disease incidence in the COVID-19 pandemic era and its association with respiratory virus and pneumococcal carriage dynamics: a time series analysis.
    Clin Infect Dis. 2023 Dec 6:ciad746. doi: 10.1093.
    >> Share

    November 2023
  130. USDAN L, Patel S, Rodriguez H, Xu X, et al
    A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in >/=12-Year-Olds.
    Clin Infect Dis. 2023 Nov 28:ciad718. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016